CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
Jiachen Xuan, Richard B Pearson, Elaine Sanij
MOLECULAR & CELLULAR ONCOLOGY | TAYLOR & FRANCIS INC | Published : 2020
Acquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
Related Projects (2)
Awarded by National Health and Medical Research Council
Awarded by Victorian Cancer Agency
This work was supported by the National Health and Medical Research Council  and the Victorian Cancer Agency [MCRF19007].